{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:59Z","timestamp":1740120119039,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K08873"],"award-info":[{"award-number":["JP19K08873"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12185-023-03644-5","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T19:02:55Z","timestamp":1690225375000},"page":"751-757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of CD8\u2009+\u2009T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma"],"prefix":"10.1007","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1836-0464","authenticated-orcid":false,"given":"Shugo","family":"Kowata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Tsukushi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Maeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Yashima-Abo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosei","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Oyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"3644_CR1","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and Brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283\u201394.","journal-title":"Lancet Oncol"},{"key":"3644_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.","journal-title":"Nat Rev Dis Primers"},{"key":"3644_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","volume":"130","author":"BM Haverkos","year":"2017","unstructured":"Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221\u20138.","journal-title":"Blood"},{"key":"3644_CR4","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167\u201375.","journal-title":"J Clin Oncol"},{"key":"3644_CR5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","volume":"17","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17:504\u201315.","journal-title":"Nat Rev Clin Oncol"},{"key":"3644_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3: e59125.","journal-title":"JCI Insight"},{"key":"3644_CR7","doi-asserted-by":"publisher","DOI":"10.3791\/60608","author":"Y Naito","year":"2020","unstructured":"Naito Y, Osa A, Masuhiro K, Hirai T, Koyama S, Kumanogoh A. Monitoring PD-1-blocking antibodies bound to T cells derived from a drop of peripheral blood. J Vis Exp. 2020. https:\/\/doi.org\/10.3791\/60608.","journal-title":"J Vis Exp"},{"key":"3644_CR8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12185-018-2508-1","volume":"108","author":"Y Kameoka","year":"2018","unstructured":"Kameoka Y, Akagi T, Murai K, Noji H, Kato Y, Sasaki O, et al. Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. Int J Hematol. 2018;108:510\u20135.","journal-title":"Int J Hematol"},{"key":"3644_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001622","volume":"8","author":"M Allouchery","year":"2020","unstructured":"Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u2265 2 immune-related adverse events in patients with cancer. J Immunother Cancer. 2020;8: e001622.","journal-title":"J Immunother Cancer"},{"key":"3644_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/cancers14040955","volume":"14","author":"M Allouchery","year":"2022","unstructured":"Allouchery M, Beuvon C, P\u00e9rault-Pochat MC, Roblot P, Puyade M, Martin M. Safety of immune checkpoint inhibitor resumption after interruption for immune-related adverse events, a narrative review. Cancers (Basel). 2022;14:955.","journal-title":"Cancers (Basel)"},{"key":"3644_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11523-022-00890-1","volume":"17","author":"DV Araujo","year":"2022","unstructured":"Araujo DV, Uchoa B, Soto-Castillo JJ, Furlan LL, Oliva M. When less may be enough: dose selection strategies for immune checkpoint inhibitors focusing on AntiPD-(L)1 agents. Target Oncol. 2022;17:253\u201370.","journal-title":"Target Oncol"},{"key":"3644_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906251","volume":"12","author":"M Jiang","year":"2022","unstructured":"Jiang M, Hu Y, Lin G, Chen C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency. Shorter Course Front Oncol. 2022;12: 906251.","journal-title":"Shorter Course Front Oncol"},{"key":"3644_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000480","volume":"4","author":"KV Lepik","year":"2020","unstructured":"Lepik KV, Fedorova LV, Kondakova EV, Zalyalov YR, Babenko EV, Lepik EE, et al. A Phase 2 study of nivolumab using a fixed dose of 40 mg (Nivo40) in patients with relapsed\/refractory Hodgkin lymphoma. Hemasphere. 2020;4: e480.","journal-title":"Hemasphere"},{"key":"3644_CR14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36:1428\u201339.","journal-title":"J Clin Oncol"},{"key":"3644_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108515","volume":"218","author":"J Damoiseaux","year":"2020","unstructured":"Damoiseaux J. The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. Clin Immunol. 2020;218: 108515.","journal-title":"Clin Immunol"},{"key":"3644_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.21873\/anticanres.14857","volume":"41","author":"R Takai","year":"2021","unstructured":"Takai R, Funakoshi Y, Suto H, Nagatani Y, Imamura Y, Toyoda M, et al. Serum soluble interleukin-2 receptor as a potential biomarker for immune-related adverse events. Anticancer Res. 2021;41:1021\u20136.","journal-title":"Anticancer Res"},{"key":"3644_CR17","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355:1423\u20137.","journal-title":"Science"},{"key":"3644_CR18","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O\u2019Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268\u201377.","journal-title":"Blood"},{"key":"3644_CR19","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","volume":"111","author":"R Yamamoto","year":"2008","unstructured":"Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111:3220\u20134.","journal-title":"Blood"},{"key":"3644_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001591","volume":"8","author":"JR Veatch","year":"2020","unstructured":"Veatch JR, Singhi N, Jesernig B, Paulson KG, Zalevsky J, Iaccucci E, et al. Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. J Immunother Cancer. 2020;8: e001591.","journal-title":"J Immunother Cancer"},{"key":"3644_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","volume":"53","author":"N Acharya","year":"2020","unstructured":"Acharya N, Madi A, Zhang H, Klapholz M, Escobar G, Dulberg S, et al. Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity. 2020;53:658-71.e6.","journal-title":"Immunity"},{"key":"3644_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41577-020-00464-0","volume":"21","author":"MD Taves","year":"2021","unstructured":"Taves MD, Ashwell JD. Glucocorticoids in T cell development, differentiation and function. Nat Rev Immunol. 2021;21:233\u201343.","journal-title":"Nat Rev Immunol"},{"key":"3644_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12185-019-02737-4","volume":"111","author":"R Ogasawara","year":"2020","unstructured":"Ogasawara R, Hashimoto D, Sugita J, Yamawaki F, Naka T, Mitsuhashi T, et al. Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma. Int J Hematol. 2020;111:475\u20139.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03644-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T15:12:44Z","timestamp":1700838764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03644-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3644"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03644-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}